A decrease in drug resistance levels of the HIV epidemic can be bad news

Bulletin of Mathematical Biology

Volumn 67, Issue 4, 2005, Pages 761-782

  Sánchez, María S ^a   Grant, Robert M ^b   Porco, Travis C ^c   Gross, Kimber L ^c   Getz, Wayne M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^c Department of Public Health ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC RESISTANCE; ARTICLE; BIOLOGICAL MODEL; DISEASE TRANSMISSION; EPIDEMIC; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; UNITED STATES;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE OUTBREAKS; DISEASE TRANSMISSION, HORIZONTAL; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HUMANS; MODELS, BIOLOGICAL; SAN FRANCISCO;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 19044362990     PISSN: 00928240     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bulm.2004.10.001     Document Type: Article

References (56)

1. P. Ammaranond, P. Cunningham, R. Oelrichs, K. Suzuki, C. Harris, L. Leas, A. Grulich, D.A. Cooper, and A.D. Kelleher Rates of transmission of antiretroviral drug resistant strains of HIV-1 J. Clin. Virol. 26 2003 153 161
2. P. Ammaranond, P. Cunningham, R. Oelrichs, K. Suzuki, C. Harris, L. Leas, A. Grulich, D.A. Cooper, and A.D. Kelleher No increase in protease resistance and a decrease in reverse transcriptase resistance mutations in primary HIV-1 infection: 1992-;2001 AIDS 17 2003 264 267
3. R.M. Anderson Mathematical and statistical studies of the epidemiology of HIV AIDS 3 1989 333 346
4. P. Bacchetti, and A.R. Moss Incubation period of AIDS in San Francisco Nature 338 1989 251 253
5. G. Bleiber, M. Munoz, A. Ciuffi, P. Meylan, and A. Telenti Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1 J. Virol. 75 2001 3291 3300
6. S.M. Blower, A.N. Aschenbach, and J.O. Kahn Predicting the transmission of drug-resistant HIV: comparing theory with data Lancet Infect. Dis. 3 2003 10 11
7. S.M. Blower, H.B. Gershengorn, and R.M. Grant A tale of two futures: HIV and antiretroviral therapy in San Francisco Science 287 2000 650 654
8. S.M. Blower, A.N. Aschenbach, H.B. Gershengorn, and J.O. Kahn Predicting the unpredictable: transmission of drug-resistant HIV Nat. Med. 7 2001 1016 1020
9. S. Bonhoeffer, and M.A. Nowak Pre-existence and emergence of drug resistance in HIV-1 infection Proc. R. Soc. Lond. B Biol. Sci. 264 1997 631 637
10. B.G. Brenner, J.P. Routy, M. Petrella, D. Moisi, M. Oliveira, M. Detorio, B. Spira, V. Essabag, B. Conway, R. Lalonde, R.P. Sekaly, and M.A. Wainberg Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection J. Virol. 76 2002 1753 1761
11. C. Castillo-Chavez, H.W. Hethcote, V. Andreasen, S.A. Levin, and W.M. Liu Epidemiological models with age structure, proportionate mixing, and cross-immunity J. Math. Biol. 27 1989 233 258
12. A. Chiesi, A. Mocroft, L.G. Dally, V. Miller, C. Katlama, B. Ledergerber, C. Pedersen, A.N. Phillips, R. Arcieri, and J.D. Lundgren Regional survival differences across Europe in HIV-positive people: the EuroSIDA study AIDS 13 1999 2281 2288
13. J. Cohen Therapies. Confronting the limits of success Science 296 2002 2320 2324
14. C. de Mendoza, J. del Romero, C. Rodriguez, A. Corral, and V. Soriano Decline in the rate of genotypic resistance to antiretroviral drugs in recent HIV seroconverters in Madrid AIDS 16 2002 1830 1832
15. N.H. Dukers, J. Goudsmit, J.B. de Wit, M. Prins, G.J. Weverling, and R.A. Coutinho Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection AIDS 15 2001 369 378
16. C. Ezzell AZT given the green light for clinical treatment of AIDS Nature 326 1987 430
17. A.C. Ghani, N.M. Ferguson, C. Fraser, C.A. Donnelly, S. Danner, P. Reiss, J. Lange, J. Goudsmit, R.M. Anderson, and F. De Wolf Viral replication under combination antiretroviral therapy: a comparison of four different regimens J. Acquir. Immune. Defic. Syndr. 30 2002 167 176
18. M.J. Gonzales, E. Delwart, S.Y. Rhee, R. Tsui, A.R. Zolopa, J. Taylor, and R.W. Shafer Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation J. Infect. Dis. 188 2003 397 405
19. J. Goudsmit, G.J. Weverling, L. van der Hoek, A. de Ronde, F. Miedema, R.A. Coutinho, J.M. Lange, and M.C. Boerlijst Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains AIDS 15 2001 2293 2301
20. R.M. Grant, F.M. Hecht, M. Warmerdam, L. Liu, T. Liegler, C.J. Petropoulos, N.S. Hellmann, M. Chesney, M.P. Busch, and J.O. Kahn Time trends in primary HIV-1 drug resistance among recently infected persons JAMA 288 2002 181 188
21. Grant, R.M., Liegler, T., Spotts, G., Hecht, F.M., 2003. Declining nucleoside reverse transcriptase inhibitor primary resistance in San Francisco, 2000-2003. XII International HIV Drug Resistance Workshop: Basic Principles & Clinical Implications, Los Cabos, Mexico
22. P.R. Harrigan, S. Bloor, and B.A. Larder Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro J. Virol. 72 1998 3773 3778
23. H.W. Hethcote, and J.W. Van Ark Epidemiological models for heterogeneous populations proportionate mixing parameter estimation and immunization programs Math. Biosci. 84 1987 85 118
24. H.W. Hethcote, and J.W. Van Ark Modeling HIV transmission and AIDS in the United States Lecture Notes in Biomathematics vol. 95 1992 Springer Berlin, New York
25. M.S. Hirsch, B. Conway, R.T. Daquila, V.A. Johnson, F. BrunVezinet, B. Clotet, L.M. Demeter, S.M. Hammer, D.M. Jacobsen, D.R. Kuritzkes, C. Loveday, J.W. Mellors, S. Vella, and D.D. Richman Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management JAMA 279 1998 1984 1991
26. M.H. Katz, S.K. Schwarcz, T.A. Kellogg, J.D. Klausner, J.W. Dilley, S. Gibson, and W. McFarland Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco Am. J. Public Health 92 2002 388 394
27. K.K. Koelsch, D.M. Smith, S.J. Little, C.C. Ignacio, T.R. Macaranas, A.J. Brown, C.J. Petropoulos, D.D. Richman, and J.K. Wong Clade B HIV-1 superinfection with wild-type virus after primary infection with drug-resistant clade B virus AIDS 17 2003 F11 F16
28. J. Koopman, C. Simon, J. Jacquez, J. Joseph, L. Sattenspiel, and T. Park Sexual partner selectiveness effects on homosexual HIV transmission dynamics J. Acquir. Immune Defic. Syndr. 1 1988 486 504
29. M.G. Law, G. Prestage, A. Grulich, P. Van de Ven, and S. Kippax Modelling the effect of combination antiretroviral treatments on HIV incidence AIDS 15 2001 1287 1294
30. T.S. Li, R. Tubiana, C. Katlama, V. Calvez, H. Ait Mohand, and B. Autran Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease Lancet 351 1998 1682 1686
31. S.J. Little, S. Holte, J.P. Routy, E.S. Daar, M. Markowitz, A.C. Collier, R.A. Koup, J.W. Mellors, E. Connick, B. Conway, M. Kilby, L. Wang, J.M. Whitcomb, N.S. Hellmann, and D.D. Richman Antiretroviral-drug resistance among patients recently infected with HIV N. Engl. J. Med. 347 2002 385 394
32. J.O. Lloyd-Smith, W.M. Getz, and H.V. Westerhoff Frequency-dependent incidence in sexually transmitted disease: portrayal of pair-based transmission and effects of illness on contact behaviour Proc. R. Soc. Lond. B 271 1539 2004 625 634
33. I.M. Longini, W.S. Clark, R.H. Byers, J.W. Ward, W.W. Darrow, G.F. Lemp, and H.W. Hethcote Statistical analysis of the stages of HIV infection using a Markov model Stat. Med. 8 1989 831 843
34. J.K. Louie, L.C. Hsu, D.H. Osmond, M.H. Katz, and S.K. Schwarcz Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-;1998 J. Infect. Dis. 186 2002 1023 1027
35. V.V. Lukashov, A. de Ronde, J.J. de Jong, and J. Goudsmit Epidemiology of HIV-1 and emerging problems Int. J. Antimicrob. Agents 16 2000 463 466
36. V.V. Lukashov, and J. Goudsmit Recent evolutionary history of human immunodeficiency virus type 1 subtype B: reconstruction of epidemic onset based on sequence distances to the common ancestor J. Mol. Evol. 54 2002 680 691
37. A. Mocroft, S. Vella, T.L. Benfield, A. Chiesi, V. Miller, P. Gargalianos, A. d'Arminio Monforte, I. Yust, J.N. Bruun, A.N. Phillips, and J.D. Lundgren Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group Lancet 352 1998 1725 1730
38. A.S. Omrani, and D. Pillay Multi-drug resistant HIV-1 J. Infect. 41 2000 5 11
39. F.J. Palella Jr., K.M. Delaney, A.C. Moorman, M.O. Loveless, J. Fuhrer, G.A. Satten, D.J. Aschman, and S.D. Holmberg Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators N. Engl. J. Med. 338 1998 853 860
40. A.N. Phillips, M. Youle, M. Johnson, and C. Loveday Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development AIDS 15 2001 2211 2220
41. D. Pillay, S. Taylor, and D.D. Richman Incidence and impact of resistance against approved antiretroviral drugs Rev. Med. Virol. 10 2000 231 253
42. R.J. Pomerantz Initiating antiretroviral therapy during HIV infection: confusion and clarity JAMA 286 2001 2597 2599
43. T.C. Porco, J. Martin, K. Page-Shafer, A. Cheng, E. Charlebois, R.M. Grant, and D. Osmond Decline in HIV infectivity following the introduction of highly active antiretroviral therapy AIDS 18 2004 81 88
44. K. Porter, D. Pillay, P. Cane, G. Dean, D. Churchill, G. Baily, S. Drake, and M. Fisher Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom BMJ 322 2001 1087 1088
45. T.C. Quinn, M.J. Wawer, N. Sewankambo, D. Serwadda, C.J. Li, F. Wabwire-Mangen, M.O. Meehan, T. Lutalo, and R.H. Gray Viral load and heterosexual transmission of human immunodeficiency virus type 1 N. Engl. J. Med. 342 2000 921 929
46. A. Ramos, D.J. Hu, L. Nguyen, K.O. Phan, S. Vanichseni, N. Promadej, K. Choopanya, M. Callahan, N.L. Young, J. McNicholl, T.D. Mastro, T.M. Folks, and S. Subbarao Intersubtype human immunodeficiency virus type 1 superinfection following seroconversion to primary infection in two injection drug users J. Virol. 76 2002 7444 7452
47. K.E. Robbins, P. Lemey, O.G. Pybus, H.W. Jaffe, A.S. Youngpairoj, T.M. Brown, M. Salemi, A.M. Vandamme, and M.L. Kalish U.S. Human immunodeficiency virus type 1 epidemic: date of origin, population history, and characterization of early strains J. Virol. 77 2003 6359 6366
48. L. Sattenspiel, J. Koopman, C. Simon, and J.A. Jacquez The effects of population structure on the spread of the HIV infection Am. J. Phys. Anthropol. 82 1990 421 429
49. S. Schwarcz, T. Kellogg, W. McFarland, B. Louie, R. Kohn, M. Busch, M. Katz, G. Bolan, J. Klausner, and H. Weinstock Differences in the temporal trends of HIV seroincidence and seroprevalence among sexually transmitted disease clinic patients, 1989-;1998: application of the serologic testing algorithm for recent HIV seroconversion Am. J. Epidemiol. 153 2001 925 934
50. M.F. Shapiro, S.C. Morton, D.F. McCaffrey, J.W. Senterfitt, J.A. Fleishman, J.F. Perlman, L.A. Athey, J.W. Keesey, D.P. Goldman, S.H. Berry, and S.A. Bozzette Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study JAMA 281 1999 2305 2315
51. I.G. Stolte, N.H. Dukers, J.B. de Wit, J.S. Fennema, and R.A. Coutinho Increase in sexually transmitted infections among homosexual men in Amsterdam in relation to HAART Sex. Transm. Infect. 77 2001 184 186
52. R. Tsui, B.L. Herring, J.D. Barbour, R.M. Grant, P. Bacchetti, A. Kral, B.R. Edlin, and E.L. Delwart Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure J. Virol. 78 2004 94 103
53. J.X. Velasco-Hernandez, H.B. Gershengorn, and S.M. Blower Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect. Dis. 2 2002 487 493
54. P.A. Volberding HIV therapy in 2003: consensus and controversy AIDS 17 (Suppl. 1) 2003 S4 S11
55. M.A. Wainberg, and G. Friedland Public health implications of antiretroviral therapy and HIV drug resistance JAMA 279 1998 1977 1983
56. S. Yerly, S. Vora, P. Rizzardi, J.P. Chave, P.L. Vernazza, M. Flepp, A. Telenti, M. Battegay, A.L. Veuthey, J.P. Bru, M. Rickenbach, B. Hirschel, and L. Perrin Acute HIV infection: impact on the spread of HIV and transmission of drug resistance AIDS 15 2001 2287 2292